| 67430-45-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• CAS: 67430-45-9
• 化学式: C22H24NaO5
• 分子量: 391.4
• InChiKey: MAARWZUYLSGGHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.62
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] POLYMORPHIC FORMS OF WARFARIN POTASSIUM AND PREPARATIONS THEREOF<br/>[FR] FORMES POLYMORPHES DE LA WARFARINE POTASSIQUE ET SES PRÉPARATIONS
  申请人：APOTEX PHARMACHEM INC

  公开号：WO2011143747A1

  公开（公告）日：2011-11-24

  There is provided crystalline solvate forms of Warfarin potassium, termed APO-I and APO-II, and processes for making APO-I and APO-II. APO-I and APO-II are polymorphic solvate forms of Warfarin potassium.

  提供了晶体溶剂形式的华法林钾，称为APO-I和APO-II，并提供了制备APO-I和APO-II的方法。APO-I和APO-II是华法林钾的多形溶剂形式。
• PROCESS FOR SYNTHESIS OF PURE WARFARIN ACID, WARFARIN ALKALI METAL SALTS AND CORRESPONDING CLATHRATES
  申请人：——

  公开号：US20020120155A1

  公开（公告）日：2002-08-29

  An improved procedure for the purification of warfarin acid. Sodium, potassium and lithium warfarin salts and the corresponding clathrates are prepared in high, pharmacopeial grade purity and good yields from the pure warfarin acid and the respective metal salt bases in suitable media.

  一种改进的制备华法林酸纯化程序。从纯华法林酸和相应的金属盐碱在适当的介质中制备高纯度、良好产率的华法林酸钠、钾和锂盐以及相应的包合物。
• Preparation of warfarin sodium from warfarin sodium-2-propanol clathrate
  申请人：——

  公开号：US20020120156A1

  公开（公告）日：2002-08-29

  The present invention is a method for producing warfarin sodium from warfarin sodium 2-propanol clathrate by thermal, nondestructive solvent expulsion. The solvent expulsion is conducted under conditions of controlled heat transfer whereby the 2-propanol is expelled from the warfarin sodium 2-propanol clathrate without decomposition of warfarin sodium or the clathrate. Heating is conducted the clathrate at a temperature from about 100° C. to about 170° C. in an active oven under air or in an inert atmosphere and at partial pressures ranging from that of a relative vacuum to atmospheric pressure. The invention also relates to pure warfarin sodium prepared according to the method of the invention and pharmaceutical compositions containing warfarin sodium.

  本发明涉及一种从华法林钠2-异丙醇包合物中通过热力非破坏性溶剂驱除制备华法林钠的方法。在控制热传递的条件下进行溶剂驱除，使2-异丙醇从华法林钠2-异丙醇包合物中驱除，而不使华法林钠或包合物降解。在活性烤箱中，在空气或惰性气氛下，以相对真空到大气压力范围内的部分压力下，将包合物加热到约100℃至约170℃的温度。本发明还涉及按照本发明方法制备的纯华法林钠以及含有华法林钠的药物组成物。
• POLYMORPHIC FORMS OF WARFARIN POTASSIUM AND PREPARATIONS THEREOF
  申请人：Bodhuri Prabhudas

  公开号：US20130143957A1

  公开（公告）日：2013-06-06

  There is provided crystalline solvate forms of Warfarin potassium, termed APO-I and APO-II, and processes for making APO-I and APO-II. APO-I and APO-II are polymorphic solvate forms of Warfarin potassium.

  提供了华法林钾的晶体溶剂型态，称为APO-I和APO-II，并提供了制备APO-I和APO-II的过程。 APO-I和APO-II是华法林钾的多晶溶剂型态。
• SYNTHESES BASED ON 2-HYDROXYACETOPHENONE
  申请人：Hoechst Celanese Corporation

  公开号：EP1089992A1

  公开（公告）日：2001-04-11